Inovio Pharmaceuticals, Inc. (INO) Financials
INO Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 193.1 million | 54.9 million |
2023-06-30 | 233.0 million | 63.7 million |
2023-03-31 | 266.6 million | 67.4 million |
2022-12-31 | 348.5 million | 126.2 million |
INO Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -36.8 million | 3.8 million |
2023-06-30 | -32.3 million | 2.9 million |
2023-03-31 | -37.0 million | 3.8 million |
2022-12-31 | -36.5 million | 3.3 million |
INO Net Income
No data available :(
INO Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 167.5 million | - | 13.3 million |
2023-06-30 | 194.9 million | - | 14.1 million |
2023-03-31 | 223.8 million | - | 14.8 million |
2022-12-31 | 253.0 million | 16.6 million | 15.5 million |
INO Shares Outstanding
INO Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 15.5 million | 9.9 million | - |
2023-06-30 | 23915 | 23.7 million | 13.5 million | - |
2023-03-31 | 296983 | 30.2 million | 13.9 million | - |
2022-12-31 | 165109 | 42.1 million | 14.0 million | - |
INO Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 388446 | 1.0 million |
2023-06-30 | 225971 | 1.1 million |
2023-03-31 | 114943 | 30.2 million |
2022-12-31 | 124666 | 1.3 million |
INO
Price: $12.10
52 week price:
Earnings Per Share: -6.09 USD
P/E Ratio: -0.70
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 3.8 million
Ebitda: -28.0 millionMarket Capitalization: 269.0 million